AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01747772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shear Wave Sonoelastography
Description: Shear Wave sonoelastography (SWE) as an ultrasound technique to measure liver fibrosis was performed on patients scheduled for non-focal liver biopsy. Results were compared with pathological score from liver biopsy.
Study NCT03147248 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P13
Description: CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks
Study NCT03147248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13
Description: CT-P13 (90 mg) by single SC injection every other week
Study NCT03147248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13
Description: CT-P13 (120 mg) by single SC injection every other week
Study NCT03147248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13
Description: CT-P13 (180 mg) by double SC 90 mg injections every other week
Study NCT03147248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13
Description: CT-P13 (120 mg) by single SC injection every other week with placebo IV at Weeks 6, 14 and 22.
Study NCT03147248 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P13
Description: CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks with placebo SC at Week 6 and every other week thereafter up to Week 28
Study NCT02062632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxepin Hydrochloride
Description: Given orally
Study NCT02062632 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study NCT02062632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02062632 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02062632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02062632 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04764058 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tienam 500
Description: Imipenem and cilastatin sodium
Study NCT04764058 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Infusion
Description: Health caregivers give the drug to the patients and monitoring the infusion rate
Study NCT05197335 — intervention group
Intervention type: DEVICE
Intervention: Chimaera short nail (length = 180 mm) in combination with one or two telescopic cephalic screws
Description: The enrolled patients will proceed by undergoing the surgery necessary for the application of the medical device under observation (Chimaera), which coincides with the start of the treatment period.
Study NCT03418454 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Buccal mucosa samples for Extraction of BACTERIAL DNA
Description: Sampling of the buccal mucosa after informed consent and prior to routine treatment. Similar sampling on follow up after 3,6,9,12 months.~Extracted BACTERIAL DNA (and not human DNA) from clinical samples will be sequenced and analyzed for the 16s rRNA (BACTERIAL ribosome).
Study NCT03775239 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness in Sex Therapy and Intimate Relationships (MSIR)
Description: Mindfulness is a mental discipline inviting intentional, non-judgmental attending of the stream of experience. Mindfulness can be seen as an adjunct to sexual therapy. Firstly, it is a way of teaching the patients and the couples to carry out sensate focus so that it can achieve its goals. Beyond this, Mindfulness may invite a stance to one's own and a partner's physical and emotional experience that is more widely beneficial. The MSIR intervention was originally developed from the Mindfulness Based Cognitive Therapy (MBCT) protocol and consists of:~Week 1: Moving into the Body Week 2: Sensing \& Exploring Week 3: Avoidance \& Intimacy- Midway individual session. Week 4: Recognising our automatic mind Week 5: Spacious Awareness Week 6: Expanding new learning
Study NCT03775239 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment-as-usual
Description: The current treatment in Sexological Clinic is an eclectic, synthetic therapy form conducted by psychiatrists, other medical doctors, psychologists and bodytherapists.~In order to implement the bio-psycho-social character of sexual dysfunctions, the current treatment takes advantage of different elements from different therapy forms combined with pharmacological treatment if necessary.~The integrated treatment combines elements from therapy's such as cognitive behavioural therapy (CBT), psychodynamic therapy and systemic therapy together with Master and Johnson's sensate focus training, body exercises training as pelvis floor exercises, introduction of sexual aids and if necessary pharmacological treatment. The therapy can be individual treatment, couple therapy (marital therapy) or group therapy.
Study NCT01229098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)
Description: LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel) Topical suspension applied once daily for up to 8 weeks
Study NCT03094026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lumosity
Description: Computer-based online cognitive training program using the Lumosity cognitive training program.
Study NCT03094026 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lumosity (waitlist control)
Description: Computer-based online cognitive training program using the Lumosity cognitive training program. The control group will receive the intervention after a waiting period of 12 weeks.
Study NCT02151279 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chitosan as wine fining agent
Description: The possibility of allergic reactions attributed to traces of chitosan used as a fining agent in wine has not been ruled out, particularly in shrimp allergic patients to whom small traces of the potential allergen may be enough to trigger anaphylactic reactions.
Study NCT02151279 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study NCT01114568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 10 mg tablet
Description: A single dose of 10 mg ertugliflozin administered as 2x5 mg material sparing formulation tablets.
Study NCT01114568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin OC Fast
Description: Formulation B) Ertugliflozin 10 mg OC Fast
Study NCT01114568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin OC Slow
Description: Formulation C) Ertugliflozin 10 mg OC Slow
Study NCT03577600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QMRT with the Cytotron®
Description: Cytotron® utilizes a combination of instantaneous magnetic field and RF at the safe, lowerend of the EM spectrum. Radiofrequency waves are computed based on individualized PD measurements of the target lesion(s) for therapeutic purpose. Its working principle is based on the underlying theory of magnetic resonance.
Study NCT02100982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Customized Care
Description: Customized Care consists of two components. The first component is a Discussion Prioritization Tool (DPT) which forces patients to make trade-offs between competing concerns to help them determine which are the most important to discuss. The second component is a customized question prompt list (QPL) to help patients communicate their priorities to the PCP. The QPL will be generated after patients use the DPT, and consists of question prompts tailored to the patients' priorities. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
Study NCT02100982 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Care As Usual
Description: Participants in this condition will interact with the research staff who will help the participant use an iPad in the waiting room to complete baseline health assessments. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
Study NCT00896168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab 3 mg per kg intravenous infusion at Week 0, 2, 6, 14 and 22.
Study NCT00896168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: MTX stable dose (7.5 to 20 mg/week equal to the dose used before participation in the study) for 22 weeks.
Study NCT05200195 — intervention group
Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Deceased or living donor liver transplantation for the cure of hepatocellular cancer on cirrhosis
Study NCT04988854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facial expression video
Description: Children are randomly allocated to one of three conditions: positive, neutral or no-food control, where they will watch either a positive, neutral, or no-food control video.
Study NCT03466333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril Maleate
Description: Enalapril maleate will be encapsulated; participants will take the drug once a day for 6 months following delivery.
Study NCT03466333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The placebo will be encapsulated; participants will take the drug once a day for 6 months following delivery. It will be identical in appearance to the IMP.
Study NCT01354158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: Dose titration of placebo, 100mg, 200mg, 400mg of Droxidopa will be given to assess the effects of Droxidopa on blood pressure and cerebral blood flow.
Study NCT04295733 — intervention group
Intervention type: BIOLOGICAL
Intervention: 4CMenB (Bexsero®) vaccine
Description: Participants will receive 2 doses of 4CMenB (Bexsero®) vaccine administered intramuscularly 1-2 months apart
Study NCT04609579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX281
Description: SNX281 will be administered as an intravenous infusion on Days 1, 8, and 15 in Cycle 1 and on Day 1 of each subsequent cycle thereafter of each 21-day cycle for up to 6 cycles, or until disease progression or unacceptable toxicity occurs. Cycle 1 length varies from 21 days in monotherapy arm to 28 days in the combination arm.
Study NCT00440648 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sevelamer carbonate, sevelamer hydrochloride
Description: Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
Study NCT00440648 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sevelamer hydrochloride, sevelamer carbonate
Description: Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
Study NCT00605800 — intervention group
Intervention type: OTHER
Intervention: blood drawn
Description: Baseline levels of bone marrow derived liver stem cells from normal healthy volunteers, which will be drawn once Two 5ml blue tubes).
Study NCT00605800 — intervention group
Intervention type: OTHER
Intervention: blood drawn
Description: At the time of preoperative testing, patients will have two extra test tubes (5cc blue top) of blood drawn for determination of pre-operative base line levels of bone marrow derived liver stem cells in peripheral blood. Intraoperatively, blood will be drawn after liver resection (two tubes of 5cc blue top). Two extra tube of blood will be drawn at the same time of routine postoperative blood drawing to determine levels of bone marrow derived liver stem cells in peripheral blood on post-operative days #1, and #3.
Study NCT03464227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0107
Description: * Pharmaceutical form: solution for infusion~* Route of administration: intravenous use
Study NCT03464227 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: intravenous infusion~* Route of administration: intravenous use
Study NCT02107118 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ARM 1: AdMSC: adipose stem cells
Description: Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. Cells are returned to the study doctor for installation into the subject every 2 weeks for 3 months.
Study NCT02107118 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ARM 2: Placebo
Description: Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.
Study NCT01725646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omacor®
Description: Subjects in 4 g and 2 g Omacor® will take this drug
Study NCT01725646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in placebo group will take this drug
Study NCT01206738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Persuasive communication
Description: The persuasive intervention aimed to reinforce the GP's beliefs about the positive consequences of managing sore throat without prescribing antibiotics.
Study NCT01206738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action plan
Description: This intervention was an action plan, supporting the GP to deal with two difficult prescribing situations: 1) a distressed patient (or often distressed parent of a child patient) 2) a patient demanding an antibiotic
Study NCT02823665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin-(9-39)
Description: A physiological study to evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.
Study NCT02823665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism.
Study NCT01575951 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI-DCE
Description: The treatment follows the standard practice including radiation dose and treatment volumes.~DCE-MRI imaging is to be performed immediately after CT simulation using the same immobilization device.~Pre-op DCE-MRI is performed and integrated into radiation simulation planning which is considered a standard technique for radiation oncologist to assess tumor volume and peritumoral edma. It will make radiation field more accurate and precise. This MRI is to be performed on the date of simulation immediately after CT simulation.~MRI image data is then transferred into radiation eclipse system, and integrated into the planning system for target contouring.~Follow the standard pre-operative radiotherapy technique using 3D conformal radiotherapy (3DCRT) or intensity modulated radiation therapy (IMRT) to deliver a total dose of 50 Gy at 2 Gy per fraction for trunk or extremity STS, or 45 Gy at 1.8 Gy per fraction for retroperitoneal STS, 5 treatments per week.
Study NCT02391012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbial l transplantation
Description: infusion of preparation of fecal preparation from a healthy donor to a colitis patient
Study NCT04291183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: horticultural therapy
Description: Flowers and vegetables will be planted with the elderly. Growth of plants planted with the elderly will be observed and maintained
Study NCT00735813 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taurolock
Description: When not in use the childrens tunneled central venous catheters are locked with the liquid Taurolock instead of heparin.
Study NCT00735813 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: When not in use the childrens tunneled central venous catheters are locked with heparin
Study NCT00767455 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HP828-101
Description: 21 day patches
Study NCT02914613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF0166 Topical Ophthalmic Solution
Study NCT01511978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous 3,4-DAP
Description: Subjects were maintained on their usual personal dose and schedule of 3,4-DAP base
Study NCT01511978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Taper 3,4-DAP to Placebo
Description: Subjects were tapered over 3 days from their usual regimen of 3,4-DAP base to placebo with up to an additional 16 hours of placebo before resuming their usual pre-study regimen of 3,4-DAP base
Study NCT01278004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethosuximide
Description: Drug will be dose escalated in order to reach maximum tolerated dose starting with 250mg.
Study NCT01278004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study NCT00703157 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: Patients undergoing left atrial circumferential pulmonary vein ostia ablation.
Study NCT00703157 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Ablation
Description: patients undergoing left atrial circumferential pulmonary vein ostia ablation via minimal invasive surgery.
Study NCT02195869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Study NCT04319263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction regimen of intravesical BCG
Description: intravesical instillation of 6 weekly doses of BCG
Study NCT04189315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asfotase alfa
Description: Asfotase alfa is administered subcutaneously.
Study NCT01206738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General intervention
Description: No additional information was provided; the general information was the information already available to GPs about antibiotic prescribing.
Study NCT02725632 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: The patients on CPAP treatment will be followed-up for 1 month.
Study NCT03857659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POC-US)
Description: POC-US evaluation will be conducted using the portable ultrasound machine, which is capable of straight-line measurements for assessment of the amniotic fluid, as well as ellipse measurements for determination of abdominal circumference. POC-US evaluation will be conducted every 4 weeks from 28-36 weeks.
Study NCT00083382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamidronate
Description: Patients will receive either pamidronate or zometa. Pamidronate is administered at a dose of 90 mg by continuous infusion over 90 minutes, every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 90 mg every 4 weeks as maintenance therapy.
Study NCT00083382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: All Patients will receive thalidomide 200 mg as an oral, once daily dose. Dose may be reduced to as low as 50 mg qod in the event of severe toxicity. Thalidomide will continue daily as tolerated until criteria to remove from study are met.~Patients will receive appropriate regimen to prevent constipation (i.e., colace, dulcolax, milk of magnesia, or lactulose)
Study NCT00083382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zometa
Description: Patients will receive either pamidronate or zometa. Zometa is administered at a dose of 4 mg by continuous infusion every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 4 mg every 4 weeks as maintenance therapy.
Study NCT04689620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser
Description: treating the venous ulcer with laser
Study NCT04689620 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser
Description: treating the venous ulcer with laser
Study NCT03857659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Routine antenatal care
Description: Routine care with fundal height measurement at each antenatal appointment every 2 weeks from 28-36 weeks. As well as clinically indicated obstetric ultrasound by a Registered Diagnostic Medical Sonographer (RDMS)
Study NCT03857659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Formal ultrasound
Description: Formal growth ultrasound performed between 36-38.6 weeks by RDMS.
Study NCT03857659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Formal ultrasound
Description: Formal growth ultrasound performed between 36-38.6 weeks by RDMS.
Study NCT03084055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eMotion
Description: eMotion is comprised of a series of weekly audio visual modules designed to increase exposure to positive activities and physical activity
Study NCT03989466 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Given IV
Study NCT03989466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Given PO
Study NCT02353546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALM